This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.
Last Updated: 10/22/2026
| Parameter | D-VRd | VRd | OR (95% CI) | P-value |
|---|---|---|---|---|
| Overall MRD negativity (≥CR) ratesa | ||||
| n | 197 | 198 | - | - |
| 10-5 threshold, % | 61.4 | 39.9 | 2.36 (1.58-3.54) | <0.0001 |
| 10-6 threshold, % | 47.7 | 27.8 | 2.33 (1.54-3.54) | <0.0001 |
| Overall MRD negativity (≥CR) ratesa (MRD-evaluable population)b | ||||
| n | 149 | 115 | - | - |
| 10-5 threshold, % | 81.2 | 68.7 | 1.91 (1.08-3.39) | 0.0209 |
| 10-6 threshold, % | 63.1 | 47.8 | 1.82 (1.11-2.99) | 0.0172 |
| MRD-negativity ≥CR ratesc | ||||
| n | 116 | 93 | - | - |
| 10-5 threshold, % | 73.3 | 55.9 | 2.05 (1.14-3.69) | - |
| 10-6 threshold, % | 48.3 | 30.1 | 2.09 (1.16-3.77) | - |
| MRD-negativity ≥CR ratesc at prespecified landmark 48 months (MRD-evaluable population) | ||||
| n | 98 | 68 | - | - |
| 10-5 threshold, % | 76.5 | 61.8 | 1.95 (0.98-3.86) | - |
| 10-6 threshold, % | 57.1 | 39.7 | 2.06 (1.09-3.89) | - |
| MRD-negativity ≥CR ratesc at prespecified landmark 72 months (MRD-evaluable population) | ||||
| n | 66 | 45 | - | - |
| 10-5 threshold, % | 80.3 | 60.0 | 2.28 (0.99-5.26) | - |
| 10-6 threshold, % | 60.6 | 37.8 | 2.32 (1.03-5.24) | - |
| Abbreviations: CI, confidence interval, CR, complete response; D-VRd, DARZLEX FASPRO + bortezomib + lenalidomide + dexamethasone; MRD, minimal residual disease; OR, odds ratio; VRd, bortezomib + lenalidomide + dexamethasone. aThe proportion of patients who achieved both MRD-negativity (at or below a 10-5 or 10-6 threshold) and ≥CR at any point during the study. bThe MRD-evaluable population was defined as patients with ≥CR, successful baseline calibration, MRD samples at each specified time point, and with ≥1 post-baseline MRD sample. cThe proportion of patients who achieved both MRD-negativity (at or below a 10-5 or 10-6 threshold) and ≥CR; calculated with the number of patients with ≥CR and with MRD sample in each window as denominators. The number of patients per arm is the same for the 10-5 and 10-6 threshold. | ||||
| Sustained MRD-negativity (≥CR) rates, % | D-VRd | VRd | OR (95% CI) | P-value |
|---|---|---|---|---|
| ITT population | ||||
| ≥24 months | ||||
| 10-5 threshold | 45.7 | 23.2 | 2.78 (1.80-4.29) | <0.0001 |
| 10-6 threshold | 31.5 | 15.2 | 2.57 (1.57-4.21) | 0.0001 |
| ≥36 months | ||||
| 10-5 threshold | 35.5 | 18.2 | 2.47 (1.55-3.94) | 0.0001 |
| 10-6 threshold | 24.2 | 12.6 | 2.19 (1.29-3.71) | 0.0029 |
| ≥48 months | ||||
| 10-5 threshold | 28.9 | 15.7 | 2.16 (1.33-3.52) | 0.0017 |
| 10-6 threshold | 19.3 | 9.6 | 2.21 (1.23-3.96) | 0.0065 |
| ≥60 months | ||||
| 10-5 threshold | 17.8 | 8.6 | 2.27 (1.23-4.20) | 0.0074 |
| 10-6 threshold | 10.2 | 2.0 | 5.37 (1.82-15.84) | 0.0006 |
| MRD-evaluable populationb | ||||
| ≥24 months | ||||
| n | 98 | 63 | - | - |
| 10-5 threshold | 91.8 | 73.0 | 4.12 (1.60-10.61) | 0.0018 |
| n | 72 | 42 | - | - |
| 10-6 threshold | 86.1 | 71.4 | 2.36 (0.88-6.29) | 0.0836 |
| ≥36 months | ||||
| n | 81 | 39 | - | - |
| 10-5 threshold | 86.4 | 73.5 | 2.38 (0.93-6.07) | 0.1010 |
| n | 57 | 36 | - | - |
| 10-6 threshold | 84.2 | 69.4 | 2.47 (0.84-7.26) | 0.1211 |
| ≥48 months | ||||
| n | 65 | 40 | - | - |
| 10-5 threshold | 88.4 | 77.5 | 2.21 (0.75-6.53) | 0.1836 |
| n | 43 | 29 | - | - |
| 10-6 threshold | 87.7 | 65.5 | 3.64 (0.99-13.30) | 0.0359 |
| ≥60 months | ||||
| n | 40 | 27 | - | - |
| 10-5 threshold | 87.5 | 63.0 | 3.30 (0.92-11.85) | 0.0342 |
| n | 25 | 10 | - | - |
| 10-6 threshold | 80.0 | 40.0 | 5.42 (0.77-38.24) | 0.0413 |
| Abbreviations: CI, confidence interval, CR, complete response; D-VRd, DARZLEX FASPRO + bortezomib + lenalidomide + dexamethasone; ITT, intention-to-treat; MRD, minimal residual disease; OR, odds ratio; VRd, bortezomib + lenalidomide + dexamethasone. aSustained MRD negativity was defined as 2 consecutive MRD negative reads ≥24, 36, 48, or 60 (±3) months apart with no MRD-positive result in between. bMRD-evaluable population defined as patients with ≥CR, successful baseline calibration, and with an MRD-negative sample followed by another MRD sample 24, 36, 48, or 60 months later, respectively. | ||||
| Characteristic | D-VRd (n=144) | VRd (n=145) |
|---|---|---|
| Median age (range), years | 72 (58-79) | 72 (51-80) |
| <70 years, n (%) | 35 (24.3) | 35 (24.1) |
| 70 to <75 years, n (%) | 68 (47.2) | 65 (44.8) |
| ≥75 years, n (%) | 41 (28.5) | 45 (31.0) |
| Male, n (%) | 65 (45.1) | 82 (56.6) |
| ECOG PSa, n (%) | ||
| 0 | 52 (36.1) | 57 (39.3) |
| 1 | 75 (52.1) | 78 (53.8) |
| 2 | 17 (11.8) | 10 (6.9) |
| ISS disease stagec, n (%) | ||
| I | 50 (34.7) | 48 (33.1) |
| II | 54 (37.5) | 57 (39.3) |
| III | 40 (27.8) | 40 (27.6) |
| Cytogenetic risk profiled | ||
| Standard | 105 (72.9) | 111 (76.6) |
| High | 20 (13.9) | 18 (12.4) |
| Unevaluable or missing | 19 (13.2) | 16 (11.0) |
| Abbreviations: D-VRd, DARZALEX FASPRO + bortezomib + lenalidomide + dexamethasone; ECOG PS, Eastern Cooperative Oncology Group performance status; FLC, free light chain; IFM, Intergroupe Francophone du Myelome; Ig, immunoglobulin; IMWG, International Myeloma Working group; ISS, International Staging System; TIE, transplant-ineligible; VRd, bortezomib + lenalidomide + dexamethasone. aECOG PS is scored on a scale of 0-5, with 0 indicating no symptoms and higher scores indicating increasing disability. bTotal additive frailty is scored on a scale of 0-5 based on age, comorbidities, and cognitive and physical conditions, with 0 indicating fit, 1 indicating intermediate fitness, and ≥2 indicating frail, per the Myeloma Geriatric Assessment score (http://www.myelomafrailtyscorecalculator.net/). cBased on the combination of serum β2-microglobulin and albumin levels. Higher stages indicate more advanced disease. dBased on fluorescence in situ hybridization; high risk was defined as the presence of del(17p), t(4;14), and/or t(14;16). | ||
| Parameter, n (%) | D-VRd (n=144) | VRd (N=145) | OR (95% CI) | P-value |
|---|---|---|---|---|
| Overall MRD negativity (≥CR) ratea | ||||
| 10-5 threshold | 61.1 | 40.0 | 2.35 (1.47-3.77) | 0.0004 |
| 10-6 threshold | 46.5 | 27.6 | 2.27 (1.39-3.71) | 0.0010 |
| Sustained MRD negativity (≥CR) rate ≥12 monthsb | ||||
| 10-5 threshold | 49.3 | 29.0 | 2.40 (1.47-3.91) | 0.0005 |
| 10-6 threshold | 37.5 | 16.6 | 3.01 (1.73-5.24) | <0.0001 |
| Sustained MRD negativity (≥CR) rate ≥24 monthsb | ||||
| 10-5 threshold | 44.4 | 23.4 | 2.62 (1.58-4.36) | 0.0002 |
| 10-6 threshold | 30.6 | 15.2 | 2.45 (1.38-4.37) | 0.0020 |
| Abbreviations: CI, confidence interval, CR, complete response; D-VRd, DARZLEX FASPRO + bortezomib + lenalidomide + dexamethasone; MRD, minimal residual disease; OR, odds ratio; TIE, transplant ineligible; VRd, bortezomib + lenalidomide + dexamethasone. aThe proportion of patients who achieved MRD negativity and ≥CR. bSustained MRD negativity was defined as 2 consecutive MRD negative reads ≥12 months (±1) or 24 months (±3) apart with no MRD-positive result in between. | ||||
| Subgroup | D-VRd | VRd | OR (95% CI) |
|---|---|---|---|
| MRD negativity (≥CR; 10-5), n/N (%) | |||
| Sex | |||
| Male | 43/65 (66.2) | 29/82 (35.4) | 3.57 (1.80-7.08) |
| Female | 45/79 (57.0) | 29/63 (46.0) | 1.55 (0.80-3.02) |
| Age | |||
| <70 years | 26/35 (74.3) | 15/35 (42.9) | 3.85 (1.40-10.59) |
| ≥70 years | 62/109 (56.9) | 43/110 (39.1) | 2.06 (1.20-3.52) |
| Region | |||
| Europe | 55/96 (57.3) | 37/90 (41.1) | 1.92 (1.07-3.44) |
| North America | 20/31 (64.5) | 12/28 (42.9) | 2.42 (0.85-6.92) |
| Other | 13/17 (76.5) | 9/27 (33.3) | 6.50 (1.64-25.76) |
| Baseline ISS | |||
| I | 33/50 (66.0) | 20/48 (41.7) | 2.72 (1.20-6.17) |
| II | 32/54 (59.3) | 26/57 (45.6) | 1.73 (0.82-3.68) |
| III | 23/40 (57.5) | 12/40 (30.0) | 3.16 (1.26-7.94) |
| Cytogenetic Risk | |||
| High risk | 10/20 (50.0) | 9/18 (50.0) | 1.00 (0.28-3.57) |
| Standard risk | 67/105 (63.8) | 44/111 (39.6) | 2.68 (1.55-4.66) |
| Baseline ECOG PS | |||
| 0 | 30/52 (57.7) | 26/57 (45.6) | 1.63 (0.76-3.47) |
| ≥1 | 58/92 (63.0) | 32/88 (36.4) | 2.99 (1.63-5.48) |
| Abbreviations: CI, confidence interval; CR, complete response; D-VRd, DARZLEX FASPRO + bortezomib + lenalidomide + dexamethasone; ECOG PS, Eastern Cooperative Oncology Group performance score; ISS, International Staging System; MRD, minimal residual disease; OR, odds ratio; TIE, transplant ineligible; VRd, bortezomib + lenalidomide + dexamethasone. | |||
| Parameter | DVRd-DR (n=355) | VRd-R (n=354) | OR (95% CI) | P-value |
|---|---|---|---|---|
| Overall MRD negativity (≥CR) ratea, % | ||||
| 10-5 threshold | 77.2 | 50.3 | 3.41 (2.46-4.73) | <0.0001 |
| 10-6 threshold | 68.7 | 36.7 | 3.88 (2.83-5.31) | <0.0001 |
| Abbreviations: CI, confidence interval; CR, complete response; DR, DARZALEX FASPRO + lenalidomide; DVRd, DARZALEX FASPRO + bortezomib + lenalidomide + dexamethasone; MRD, minimal residual disease; OR, odds ratio; R, lenalidomide; VRd, bortezomib + lenalidomide + dexamethasone. aProportion of patients who achieved MRD negativity and ≥CR. Nominal 2-sided P-values reported are not adjusted for multiplicity. | ||||
| Parameter | DVRd-DR | VRd-R | OR (95% CI) | P-value |
|---|---|---|---|---|
| Patients without MRD negativity (≥CR) at the end of consolidationa, n/N (%) | ||||
| Achieved MRD-negativity at 10-5 and ≥CR during maintenance | 85/134 (63.4) | 72/149 (48.3) | 1.86 (1.15-2.99) | 0.0108 |
| Achieved MRD-negativity at 10-6 and ≥CR during maintenance | 136/212 (64.2) | 81/206 (39.3) | 2.76 (1.86-4.10) | <0.0001 |
| Abbreviations: CI, confidence interval; CR, complete response; DR, DARZALEX FASPRO + lenalidomide; DVRd, DARZALEX FASPRO + bortezomib + lenalidomide + dexamethasone; MRD, minimal residual disease; NGS, next-generation sequencing; OR, odds ratio; R, lenalidomide; VRd, bortezomib + lenalidomide + dexamethasone. aIncludes patients who tested MRD positive, patients with indeterminate results, patients without NGS index clone, patients with <CR, and patients who did not provide samples. | ||||
| Parameter | DVRd-DR (n=355) | VRd-R (n=354) | OR (95% CI) | P-value |
|---|---|---|---|---|
| 12-month sustained MRD-negativity, % | ||||
| 10-5 threshold | 70.4 | 36.2 | 4.29 (3.12-5.89) | <0.0001 |
| 10-6 threshold | 59.4 | 25.4 | 4.40 (3.19-6.08) | <0.0001 |
| 24-month sustained MRD-negativity, % | ||||
| 10-5 threshold | 65.9 | 31.4 | 4.34 (3.16-5.97) | <0.0001 |
| 10-6 threshold | 55.5 | 21.5 | 4.69 (3.36-6.55) | <0.0001 |
| 36-month sustained MRD-negativity, % | ||||
| 10-5 threshold | 60.0 | 26.8 | 4.25 (3.08-5.88) | <0.0001 |
| 10-6 threshold | 47.6 | 17.2 | 4.47 (3.15-6.34) | <0.0001 |
| Abbreviations: CI, confidence interval; CR, complete response; DR, DARZALEX FASPRO + lenalidomide; DVRd, DARZALEX FASPRO + bortezomib + lenalidomide + dexamethasone; MRD, minimal residual disease; OR, odds ratio; R, lenalidomide; VRd, bortezomib + lenalidomide + dexamethasone. aSustained MRD negativity was defined as 2 consecutive MRD negative reads ≥12 months (±1) or ≥24 or ≥36 months (±3) apart with no MRD-positive result in between. Nominal 2-sided P-values reported are not adjusted for multiplicity. | ||||
| D-R (n=99) | R (n=101) | |
|---|---|---|
| Median age (range), years | 63 (35-77) | 62 (35-78) |
| <65 years, n (%) | 61 (61.6) | 61 (60.4) |
| 65-70 years, n (%) | 23 (23.2) | 21 (20.8) |
| ≥70 years, n (%) | 15 (15.2) | 19 (18.8) |
| Sex, n (%) | ||
| Male | 61 (61.6) | 58 (57.4) |
| Female | 38 (38.4) | 43 (42.6) |
| Race, n (%) | ||
| White | 67 (67.7) | 68 (67.3) |
| Black or African American | 20 (20.2) | 24 (23.8) |
| Asian | 5 (5.1) | 1 (1) |
| American Indian or Alaska Native | 0 (0) | 1 (1) |
| Othera | 5 (5.1) | 5 (5) |
| NR | 2 (2) | 2 (2) |
| ECOG PS, n (%) | ||
| 0 | 45 (45.5) | 55 (54.5) |
| 1 | 52 (52.5) | 44 (43.6) |
| 2 | 2 (2) | 2 (2) |
| ISS disease stageb, n (%) | ||
| I | 40 (44) | 38 (38.8) |
| II | 28 (30.8) | 37 (37.8) |
| III | 23 (25.3) | 23 (23.5) |
| Median induction cycles (range)c, n | 5 (4-8) | 5 (4-8) |
| Cytogenetic risk at diagnosisd, n (%) | ||
| Standard risk | 63 (68.5) | 66 (74.2) |
| High riske | 22 (23.9) | 15 (16.9) |
| del(17p) | 13 (14.1) | 3 (3.4) |
| t(4;14) | 10 (10.9) | 12 (13.5) |
| t(14;16) | 6 (6.5) | 7 (7.9) |
| Unknown | 7 (7.6) | 8 (9) |
| Revised cytogenetic risk at diagnosisf | ||
| Standard risk | 52 (55.9) | 53 (59.6) |
| High riskg | 32 (34.4) | 30 (33.7) |
| del(17p) | 13 (14) | 3 (3.4) |
| t(4;14) | 10 (10.8) | 12 (13.5) |
| t(14;16) | 6 (6.5) | 7 (7.9) |
| t(14;20) | 1 (1.1) | 2 (2.2) |
| gain/amp(1q21) | 16 (17.2) | 22 (24.7) |
| Unknown | 9 (9.7) | 6 (6.7) |
| Abbreviations: D-R, DARZALEX FASPRO+lenalidomide; ECOG PS, Eastern Cooperative Oncology Group performance status; ISS, International Staging System; ITT, intention-to-treat; NR, not reported; R, lenalidomide. aPatients reporting multiple races. bD-R vs R: n=91 vs n=98, respectively. cD-R vs R: n=98 vs n=99, respectively. dD-R vs R: n=92 vs n=89, respectively. eHigh risk is defined as positive for any of del(17p), t(14;16), or t(4;14). fD-R vs R: n=93 vs n=89, respectively. gRevised high-risk cytogenetics is defined as ≥1 abnormality from del(17p), t(4;14), t(14;16), t(14;20), and gain/amp(1q21). | ||
Efficacy
| Parameter | D-R | R | ORa (95% CI) | P Valueb |
|---|---|---|---|---|
| Overall MRD-negativity conversion rate, | ||||
| 10-5 sensitivity | 60.6 | 28.7 | 3.92 (2.16-7.14) | <0.0001 |
| 10-6 sensitivity | 36.4 | 14 | 3.59 (1.78-7.23) | 0.0003 |
| Overall MRD-negativity (≥CR) conversion rate, %c | ||||
| 10-5 sensitivity | 55.6 | 23.8 | 4.11 (2.23-7.59) | <0.0001 |
| 10-6 sensitivity | 35.4 | 10.9 | 4.55 (2.14-9.66) | <0.0001 |
| MRD-negativity accumulative conversion rate at 12 months from start of maintenance, % | ||||
| 10-5 sensitivity | 50.5 | 18.8 | 4.51 (2.37-8.57) | <0.0001 |
| 10-6 sensitivity | 23.2 | 5.0 | 5.97 (2.15-16.58) | 0.0002 |
| MRD-negativity accumulative conversion rate at 18 months from start of maintenance, % | ||||
| 10-5 sensitivity | 56.6 | 21.8 | 4.81 (2.57-9.00) | <0.0001 |
| 10-6 sensitivity | 30.3 | 8.9 | 4.44 (1.98-9.96) | 0.0001 |
| MRD-negativity accumulative conversion rate at 24 months from start of maintenance, % | ||||
| 10-5 sensitivity | 60.6 | 26.7 | 4.33 (2.36-7.94) | <0.0001 |
| 10-6 sensitivity | 35.4 | 10.9 | 4.51 (2.13-9.56) | <0.0001 |
| Sustained MRD-negativity (10-5), % | ||||
| ≥6 monthsd | 42.4 | 17.8 | 3.45 (1.80-6.61) | 0.0002 |
| ≥12 monthsd | 29.3 | 7.9 | 4.88 (2.09-11.38) | 0.0001 |
| Abbreviations: CI, confidence interval; CR, complete response; D-R, DARZALEX FASPRO + lenalidomide; ITT, intention-to-treat; MRD, minimal residual disease; OR, odds ratio; R, lenalidomide. aMantel–Haenszel estimate of the common OR for stratified tables was used. The stratification factor was BL cytogenetic risk per investigator assessment (high vs standard/unknown), as used for randomization. An OR >1 indicates an advantage for D-R. bP value from Fisher’s exact test. cAt a median follow-up of 40.3 months. dDefined as those who achieved MRD-negative status (at 10–5 | ||||
| Subgroup, n/N (%) | D-R | R | OR (95% CI) |
|---|---|---|---|
| Sex | |||
| Male | 37/61 (60.7) | 17/58 (29.3) | 3.72 (1.73-7.98) |
| Female | 23/38 (60.5) | 12/43 (27.9) | 3.96 (1.56-10.05) |
| Age | |||
| <65 years | 35/61 (57.4) | 19/61 (31.1) | 2.98 (1.42-6.25) |
| ≥65 years | 25/38 (65.8) | 10/40 (25.0) | 5.77 (2.16-15.38) |
| Race | |||
| White | 36/67 (53.7) | 21/68 (30.9) | 2.60 (1.29-5.25) |
| Black or African American | 16/20 (80.0) | 7/24 (29.2) | 9.71 (2.38-39.61) |
| Other | 8/12 (66.7) | 1/9 (11.1) | 16.00 (1.45-176.45) |
| Weight | |||
| ≤70 kg | 15/23 (65.2) | 4/18 (22.2) | 6.56 (1.61-26.72) |
| >70 kg | 45/76 (59.2) | 25/81 (30.9) | 3.25 (1.69-6.27) |
| Baseline ECOG PS score | |||
| 0 | 27/45 (60.0) | 12/55 (21.8) | 5.37 (2.24-12.89) |
| ≥1 | 33/54 (61.1) | 17/46 (37.0) | 2.68 (1.19-6.03) |
| ISS staging at diagnosis | |||
| I | 22/40 (55.0) | 14/38 (36.8) | 2.10 (0.85-5.19) |
| II | 15/28 (53.6) | 11/37 (29.7) | 2.73 (0.98-7.59) |
| III | 18/23 (78.3) | 3/23 (13.0) | 24.00 (5.01-114.97) |
| Cytogenetic risk at diagnosis | |||
| High riska | 11/22 (50.0) | 3/15 (20.0) | 4.00 (0.88-18.22) |
| Standard risk | 40/63 (63.5) | 20/66 (30.3) | 4.00 (1.92-8.33) |
| Revised cytogenetic risk at diagnosis | |||
| High riskb | 19/32 (59.4) | 6/30 (20.0) | 5.85 (1.87-18.27) |
| Standard risk | 32/52 (61.5) | 18/53 (34.0) | 3.11 (1.40-6.90) |
| Cytogenic risk per IMS 2024 criteria | |||
| High riskc | 9/17 (52.9) | 0/8 (0) | NE (NE-NE) |
| Standard risk | 42/67 (62.7) | 25/68 (36.8) | 2.89 (1.44-5.81) |
| Abbreviations: CI, confidence interval; D-R, DARZALEX FASPRO + lenalidomide; ECOG PS, Eastern Cooperative Oncology Group performance status; ISS, International Staging System; MRD, minimal residual disease; NE, not evaluable; OR, odds ratio; R, lenalidomide. aHigh-risk cytogenetics are defined as ≥1 abnormality including del(17p), t(4;14), and/or t(14;16). bRevised high-risk cytogenetics are defined as ≥1 abnormality including del(17p), t(4;14), t(14;16), t(14;20), and/or gain/amp(1q21). cHigh risk per the modified IMS 2024 criteria is defined as the presence of ≥20% del(17p), or the association of ≥2 of the following: t(4;14) or t(14;16) or t(14;20); gain/amp(1q21); or del(1p32) [in the AURIGA study, data were not available on TP53 mutations, baseline ß2M, and creatinine levels and differentiation between monoallelic versus biallelic del(1p32)]. | |||
| Parameter | D-R | R | ORa | P-Valueb |
|---|---|---|---|---|
| Overall MRD-negativity conversion ratec, % | ||||
| 10-5 threshold | 60.6 | 29.7 | 3.74 | <0.0001 |
| 10-6 threshold | 36.4 | 13.9 | 3.59 | 0.0003 |
| Sustained MRD-negativity rated, % | ||||
| 10-5 threshold | 29.3 | 7.9 | 4.88 | 0.0001 |
| 10-6 threshold | 19.2 | 2.0 | 11.75 | <0.0001 |
| Abbreviations: D-R, DARZALEX FASPRO + lenalidomide; MRD, minimal residual disease; OR, odds ratio; PD, progressive disease; R, lenalidomide.aMantel-Haenszel estimate of the common OR for stratified tables was used. The stratification factor was baseline cytogenetic risk per investigator assessment (high vs standard/unknown), as used for randomization. An OR >1 indicates an advantage for D-R.bP value from Fisher’s exact test. cDefined as the proportion of patients who achieved MRD negativity (10-5 or 10-6) by bone marrow aspirate at any time after baseline and prior to PD and subsequent antimyeloma therapy.dDefined as those who achieved MRD negative status (at 10-5 or 10-6) in 2 bone marrow aspirate assessments with a minimum of 12 months apart (based on specified endpoint), without any assessment showing MRD-positive status in between assessments. | ||||
| Patients, n/N (%) | D-R (n=99) | R (n=101) |
|---|---|---|
| MRD-negative conversiona,d | ||
| 10-5 sensitivityb | 60/99 (60.6) | 30/101 (29.7) |
| Standard riskc | 45/70 (64.3) | 25/74 (33.8) |
| High risk | 11/22 (50.0) | 3/15 (20.0) |
| 10-6 sensitivitye | 36/99 (36.4) | 14/101 (13.9) |
| Standard riskc | 27/70 (38.6) | 12/74 (16.2) |
| High risk | 6/22 (27.3) | 2/15 (13.3) |
| 10-5 only sensitivityf | 24/99 (24.2) | 16/101 (15.8) |
| Standard riskc | 18/70 (25.7) | 13/74 (17.6) |
| High risk | 5/22 (22.7) | 1/15 (6.7) |
| MRD-positive recurrenced | ||
| 10-5 sensitivity | ||
| Standard riskc | 9/45 (20.0) | 8/25 (32.0) |
| High risk | 6/11 (54.5) | 1/3 (33.3) |
| 10-6 sensitivity | ||
| Standard riskc | 3/27 (11.1) | 5/12 (41.7) |
| High risk | 2/6 (33.3) | 1/2 (50.0) |
| 10-5 only sensitivity | ||
| Standard riskc | 7/18 (38.9) | 6/13 (46.2) |
| High risk | 5/5 (100) | 1/1 (100) |
| Abbreviations: D-R, DARZALEX FASPRO + lenalidomide; MRD, minimal residual disease; R, lenalidomide.aIncludes patients with ≥1 negative MRD test at the 10–5 threshold.bOf the 11 high-risk patients in the D-R group, 6 had del(17p), 4 had t(4;14), and 4 had t(14;16); all 3 high-risk patients in the R group had only t(4;14). cFor this analysis, the standard-risk subgroups included patients with an incomplete cytogenetic panel. dMRD-negative conversion and MRD-positive recurrence rates are among patients with cytogenetic results for del(17p), t(4;14), and/or t(14;16) at diagnosis. One patient with MRD-positive recurrence in the D-R arm had no cytogenetic test results for del(17p), t(4;14), or t(14;16).eOf the 6 high-risk patients in the D-R group, 3 had del(17p), 3 had t(4;14), and 3 had t(14;16); both high-risk patients in the R group had only t(4;14). fOf the 5 high-risk patients in the D-R group, 3 had del(17p), 1 had t(4;14), and 1 had t(14;16); the 1 high-risk patient in the R group had only t(4;14). | ||
| Parameter | 10-5 sensitivity | 10-6 sensitivity | ||
|---|---|---|---|---|
| D-R (n=99) | R (n=101) | D-R (n=99) | R (n=101) | |
| MRD status at 12 months from start of maintenance, % | ||||
| MRD-negative | 50.0 | 19.6 | 22.4 | 5.1 |
| MRD-positive | 29.6 | 52.6 | 52.0 | 65.7 |
| Indeterminate/missed | 8.2 | 8.2 | 13.3 | 9.1 |
| Treatment discontinuation | 12.2 | 19.6 | 12.2 | 20.2 |
| MRD status at 18 months from start of maintenance, % | ||||
| MRD-negative | 43.9 | 13.4 | 23.5 | 7.1 |
| MRD-positive | 29.6 | 39.2 | 42.9 | 45.5 |
| Indeterminate/missed | 10.2 | 12.4 | 17.3 | 12.1 |
| Treatment discontinuation | 16.3 | 35.1 | 16.3 | 35.4 |
| MRD status at 24 months from start of maintenance, % | ||||
| MRD-negative | 42.9 | 16.5 | 26.5 | 4.0 |
| MRD-positive | 25.5 | 28.9 | 38.8 | 40.4 |
| Indeterminate/missed | 11.2 | 12.4 | 14.3 | 13.1 |
| Treatment discontinuation | 20.4 | 42.3 | 20.4 | 42.4 |
| Abbreviations: D-R, DARZALEX FASPRO + lenalidomide; MRD, minimal residual disease; R, lenalidomide. aIncludes patients with baseline MRD positivity | ||||
| Parameter | D-R | R | HR (95% CI)a | P-Valueb |
|---|---|---|---|---|
| Median PFS, months | NR | 47.2 | 0.55 (0.33-0.91) | 0.0183 |
| PFS events in patients achieving MRD-negative conversion, % (n/N) | ||||
| 10-5 sensitivity | 10.0 (6/60) | 13.3 (4/30) | 0.69 (0.20-2.47) | - |
| 10-6 sensitivity | 2.8 (1/36) | 21.4 (3/14) | 0.23 (0.02-2.27) | - |
| PFS events in patients achieving sustained MRD-negativityc, % (n/N) | ||||
| 10-5 sensitivity | 0/29 | 25.0 (2/8) | - | - |
| 10-6 sensitivity | 0/19 | 0/2 | - | - |
| Abbreviations: CI, confidence interval; D-R, DARZALEX FASPRO + lenalidomide; MRD, minimal residual disease; HR, hazard ratio; PFS, progression free survival; R, lenalidomide. aHR and 95% CI from a Cox proportional hazards model with treatment as the sole explanatory variable and stratified by baseline cytogenetic risk (high vs standard/unknown), as used for randomization. A HR <1 indicates an advantage for D-R.bP value from stratified log-rank test. cPatients who achieved sustained MRD negativity lasting ≥12 months | ||||
| Parameter | D-Rb | R |
|---|---|---|
| PD/death in patients with MRD-positive (10–5) recurrence, % (n/N) | 31.3 (5/16) | 11.1 (1/9) |
| Median (range) time between recurrence and PD/death, months | 15.9 (5.6-19.2) | 13.1 (13.1-13.1) |
| Abbreviations: D-R, DARZALEX FASPRO + lenalidomide; MRD, minimal residual disease; PD, progressive disease; R, lenalidomide. aPer investigator assessmentbAmong D-R patients, 3 had cytogenetic high risk at diagnosis, 4 had MRD positive (10-5) recurrence within 7 months | ||
A literature search of MEDLINE®
In response to your specific request, summarized in this response are the relevant data from company-sponsored studies pertaining to this topic.
| 1 | Usmani SZ, Facon T, Hungria V, et al. Daratumumab plus bortezomib, lenalidomide and dexamethasone for transplant-ineligible or transplant-deferred newly diagnosed multiple myeloma: the randomized phase 3 CEPHEUS study. Nat Med. 2025;31(4):1195-1202. |
| 2 | |
| 3 | |
| 4 | |
| 5 | |
| 6 | |
| 7 | |
| 8 | |
| 9 | |
| 10 | |
| 11 | |
| 12 | |
| 13 | |
| 14 | |
| 15 | |
| 16 |
Would you like to clear and leave your conversation? Message history will be lost.